EATONTOWN, N.J., Jan. 15 /PRNewswire/ -- Roberts Pharmaceutical
Corporation (Amex: RPC) yesterday afternoon presented at the 17th annual
Hambrecht & Quist Healthcare Conference in San Francisco. The Company's
presentation at this meeting of investment managers reflected Roberts'
optimism over its long-term growth prospects.
Based on currently available information, Roberts expects strong
incremental annual growth over the next few years to be supported by
anticipated increased market penetration of its new high-margin products
Agrylin(R), ProAmatine(R), and Pentasa(R).
Revenue growth should be further enhanced by potential acquisitions of
in-market products and future product flow from the development pipeline.
With regard to the former, the Company actively pursues opportunities to
acquire high-potential, but under-promoted drugs that can add to both its top
and bottom lines, enhance cash flow, complement its pipeline programs, and are
consistent with its marketing strengths.
Roberts believes that annual growth in profitability over the coming years
should be driven by a combination of factors including anticipated growth in
revenues, further strengthening in gross profit margins, and additional
reductions in sales, general, and administration (SG&A) expenses as a
percentage of revenues.
The Company's product pipeline includes several compounds in late-stage
development that collectively represent potential future U.S. sales estimated
at over $1.5 billion. Many of these products also represent worldwide
opportunities for Roberts.
Among the compounds most advanced in clinical development is Dirame(TM), a
potent opioid analgesic with low addiction potential and with an estimated
future U.S. sales potential of $150 million. Dirame is currently in Phase III
studies.
Additionally, Emitasol(R), a patented intranasal anti-emetic, being
investigated for the treatment of diabetic gastroparesis and delayed onset
emesis should enter Phase III studies in the near term. Also nearing Phase
III study is a compound designated as RL0903. Because of certain contractual
reasons, Roberts cannot, at this time, provide detailed information about
RL0903 except to note that this is a urology/oncology compound with an
estimated U.S. sales potential of $300 million.
Roberts Pharmaceutical Corporation, with operating subsidiaries in the
United States, Canada and the United Kingdom, focuses on innovative and
value-added therapeutics for gastroenterology, cardiology, neurology,
oncology/hematology, and urology. Roberts actively pursues its strategy of
"Search & Develop" to identify and acquire novel drug candidates to advance
through late-stage development into the market while also pursuing
opportunities to acquire and bring commercially available specialty
pharmaceuticals to their full potential.
This release contains forward-looking statements which are based on
assumptions and external factors, including assumptions relating to, but not
limited to regulatory action, product pricing, competitive market conditions,
unaudited financial data, new product development and other risks or
uncertainties detailed from time to time in Roberts filings with the
Securities and Exchange Commission. These forward-looking statements
represent the Company's judgment as of the date of this release and any
changes in the assumptions or external factors could produce significantly
different results.
This and past press releases of Roberts Pharmaceutical Corporation are
available through the internet at the Company's home page at
http://www.robertspharm.com.
SOURCE Roberts Pharmaceutical Corporation
 back to top
Related links:
http://www.robertspharm.com
CONTACT:
Janet Browning of Roberts Pharmaceutical
Corporation, 732-676-1200, ext. 3077, or fax, 732-676-1300
|
